Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT03620032
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Phase II Umbrella Study Directed by Next Generation Sequencing
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Guiyang Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT03557112
- Locations
- 🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Hangzhou Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT03554889
- Locations
- 🇨🇳
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03469531
- Locations
- 🇨🇳
Zhujiang Hospital, Guangzhou, Guangdong, China
Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Peking University
- Target Recruit Count
- 55
- Registration Number
- NCT03400592
- Locations
- 🇨🇳
Peking cancer hospital, Beijing, Beijing, China
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03025958
- Locations
- 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT02858206
- Locations
- 🇨🇳
Zefen Xiao, Beijing, Beijing, China
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 60
- Registration Number
- NCT02705612
- Locations
- 🇨🇳
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2018-10-16
- Target Recruit Count
- 30
- Registration Number
- NCT02672241
- Locations
- 🇨🇳
he Department of Radiation Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.